Permanent radioactive seed implants are a form of radiation therapy for prostate cancer. The terms "brachytherapy" or "internal radiation therapy" might also be used to describe this procedure.
During the procedure, radioactive (iodine-125 or I-125) seeds are implanted into the prostate gland using ultrasound guidance. The number of seeds and where they are placed is determined by a computer-generated treatment plan tailored for each patient. About 100 seeds are commonly implanted.
The implants remain in place permanently, and become biologically inert (inactive) after about 10 months. This technique allows a high dose of radiation to be delivered to the prostate with limited damage to surrounding tissues.
Compared to external radiation, which requires 7 to 7 ½ weeks of daily treatments, convenience is a major advantage of this treatment option because it is a single outpatient procedure.
Who is eligible for this procedure?
Permanent implants are relatively low-energy sources, and therefore have limited tissue penetration. A well-done implant will treat the prostate and the surrounding few millimeters of adjacent tissue.
Therefore, the best candidates for this procedure are patients who have a cancer that is contained within or near the prostate. Patients with prostate cancer that is invading nearby structures like the bladder or rectum are not appropriate for this technique.
What happens during the procedure?
The entire procedure takes about 90 minutes. Most patients go home the same day.
A radiation oncologist and urologist perform the procedure. Both doctors are actively involved in all aspects of the implantation, from the planning to the post-operative care. During the procedure, the urologist provides ultrasound guidance and the radiation oncologist places the radioactive seeds. The prostate ultrasound and treatment planning are both done at the same time as implantation of the radioactive seeds.
- After general or spinal anesthesia, the legs are elevated and padded very carefully.
- The ultrasound probe is inserted into the rectum and is used to take pictures of the prostate. The probe remains in place throughout the procedure.
- The ultrasound images are used to generate an individualized treatment plan. Then the radioactive seeds are loaded into the designated number of needles.
- In a specific order, each needle is inserted through the skin in the perineum (the area between the base of the scrotum and the anus) and into the prostate using continuous ultrasound guidance. Once accurate needle placement is confirmed, the seeds in that needle are released. This process is continued until all of the radioactive seeds have been implanted. No surgical incision or cutting is necessary.
- If there is some blood in the urine, a catheter might be placed into the bladder for a short period of time to insure proper drainage. All patients are taught how to catheterize themselves at home to drain urine from the bladder should that be necessary.
What are the results?
The success rate depends on the risk category of the prostate cancer and the type of success that is being measured. The most common measurement is related to PSA assessments after treatment. Using this method, the 5-year success rates for the various risk groups are:
- Low-risk (PSA < 10="" ng/ml="" and="" gleason="" score="">< 7)="" = 95%
- Intermediate-risk (PSA < 10="" ng/ml="" and="" a="" gleason="" score="" of="" 7="" or="" psa="" 10="" ng/ml="" to="" 20="" ng/ml="" and="" a="" gleason="" score="" of="" 6)="" = 90%
- High-risk (PSA > 20 ng/mL or Gleason Score > 7 and any PSA) = 74%
It is important to know that these numbers are heavily dependent on how frequently the PSA test is drawn after therapy. We draw PSA tests every 6 months after therapy. In reports of similar rates from other sources, one must make sure that the PSA tests are being drawn at least this frequently or a comparison cannot be made.
What are the side effects?
Urinary symptoms are the most common side effects of the procedure. These symptoms include frequent urination and a need to get to the bathroom quickly. There might also be burning with urination and, in a few cases, an inability to empty the bladder completely. These symptoms can usually be managed with medicine, and improve over time. Temporary self-catheterization might be necessary to help drain the bladder if it cannot be emptied adequately, but this is rarely needed (about 5% of patients require it).
Urinary incontinence is rare in general. The risk might be somewhat increased in patients who have undergone a previous surgical procedure to remove a part of the prostate called a transurethral resection of the prostate (TURP). This risk can be minimized by performing a careful prostate ultrasound before the procedure to determine how much prostate tissue is still present to implant.
Rectal bleeding occurs in less than 1% of patients. Diarrhea is rare.
The impotence rate for those fully potent prior to the procedure at five years after the procedure is approximately 25 percent using brachytherapy alone. If hormone therapy is added, the impotence rate rises to 50 percent.
Close, prolonged contact (sitting in the lap) with young children should be limited to 20 minutes per hour for the first two months after the procedure. It is safe to sleep in the same bed if your partner/spouse is NOT PREGNANT. If your partner/spouse is PREGNANT, separate sleeping arrangements will be necessary for two months. If you have other questions, please call your radiation oncologist or urologist.
- National Cancer Institute. Understanding Brachytherapy (A Type of Internal Radiation Therapy) Accessed 11/9/2016. National Cancer Institute. Treatment Choices for Men With Early-Stage Prostate Cancer Accessed 11/9/2016. Urology Care Foundation/American Urological Association. Prostate cancer: radiation therapy Accessed 11/9/2016.
© Copyright 1995-2016 The Cleveland Clinic Foundation. All rights reserved
This information is provided by the Cleveland Clinic and is not intended to replace the medical advice of your doctor or health care provider. Please consult your health care provider for advice about a specific medical condition. This document was last reviewed on: 10/31/2016...index#5566